Sponsor decision

This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on men undergoing penile implant surgery for the first time. The patients are randomized in a 2:1 ratio of active to sham treatment groups.

Erectile Dysfunction (ED) is a condition with an inability to develop or maintain an erection of the penis upon sexual stimulation. It occurs in association with aging, chronic illnesses and various modifiable risk factors. Amongst the modifiable risk factors, ED shares the most common risk factors with Coronary Artery Disease (CAD) which are smoking, hypertension and hyperlipidemia. Even though it is not a part of normal aging, it is seen in 52% of men in the age group 40 to 70 years, with a higher rate in the men more than 70 years.

VIAGENEX Max is a semi-transparent, collagenous membrane intended for soft tissue barrier or wound covering, derived from umbilical cord membrane. A total of 50 subjects with ED meeting the eligibility criteria will be randomized. The treatment graft will be placed into the wound at time of surgery. The treatment group will receive the VIAGENEX graft and the sham group will receive the standard of care for this surgery.

Inclusion Criteria:

• The patient must be willing and able to provide informed consent
• The patient is a male between >/= 30 and =/< 70 years of age
• The patient has ED based of International Index of Erectile Dysfunction (IIEF) scores
• The patient has been in a stable relationship for over 3 months prior to enrollment
• A minimum of 2 sexual attempts per month for at least one month prior to enrollment - as documented by IIEF
• The patient is suffering from erectile dysfunction and undergoing penile implant surgery for the first time
• IIEF-EF score between 16 and 25
• Testosterone level 300-1000 ng/dL within 1 month prior to enrollment
• A1C level </= 7% within 1 month prior to enrollment

Exclusion Criteria:

• The patient is currently or has participated in another study within the past three months that may interfere with the results or conclusions of this study
• The patient is under judicial protection (prison or custody)
• The patient is an adult under guardianship
• The patient refuses to sign the consent
• History of radical prostatectomy or extensive pelvic surgery
• Evidence of venous leak
• Past radiation therapy of the pelvic region within 12 months prior to enrollment
• Recovering from any cancer within 12 months prior to enrollment
• Neurological disease such as Alzheimer's or Parkinson's disease which affects erectile function at the discretion of the investigator
• Psychiatric diagnosis or medications such as antidepressants, anxiolytic, antipsychotic that affects erectile function or any other medications at the discretion of the investigator
• Anatomical malformation of the penis, including Peyronie's disease
• Testosterone level <300 or >1000 ng/dL within 1 month prior to enrollment
• A1C level > 7% within 1 month prior to enrollment or history of insulin dependent diabetes
• The patient is taking blood thinners and has an international normalized ratio >3
• Received shockwave treatment at least 6 months before enrollment

Male

IPD will not be shared.

Subjects will not be told which treatment group they receive until the end of study participation.